AVA-921, “Heavy Testosterone”, deuterated testosterone, or d3-testosterone (d3-T) is an androgen or androgen receptor agonist underneath improvement for remedy of ladies with breast most cancers, sexual dysfunction, and different points. However we could be certain males within the underground will likely be concerned with its results as a considerably much less aromatizable type of testosterone – subsequently making it “dry” or much less estrogenic. On this video, I speak with Omar Hajmousa, Pharm-D, my Director of Training & Technique for the Testosteronology Society™ about AVA-921 from a hurt discount and pharmacological standpoint.
Key Particulars About AVA-291 (d3-T):
Mechanism: It’s a deuterated analog of testosterone (the place hydrogen atoms are changed by deuterium), which makes it extremely immune to the aromatase enzyme, stopping its conversion into estradiol.
Goal Indications: Primarily aimed toward addressing low libido and muscle loss in girls (together with these utilizing GLP-1 agonists). Additionally it is being investigated to be used in males with therapy-induced gynecomastia and in treating ER+ breast most cancers.
Security Profile: Preclinical research point out that d3-T is as efficient as testosterone at androgen receptor activation however has roughly 1,000-fold much less potential to stimulate breast most cancers cell proliferation.
Scientific Improvement: Aviva Bio is getting ready to provoke Section I trials in early 2026, with the purpose of it being the primary FDA-approved testosterone remedy designed particularly for ladies.
Patent Safety: The compound is roofed by patents extending to no less than 2041.
Observe: The search outcomes additionally point out an older, unrelated, anti-androgen compound known as TSAA-291. The knowledge above refers back to the fashionable Aviva Biopharm drug, AVA-291.
Main Scientific Indications
Aviva Bio is positioning AVA-291 as a safer various for a number of circumstances the place testosterone’s aromatization is a limiting issue:
Girls’s Well being: Supposed to be the primary FDA-approved testosterone remedy particularly for ladies to deal with low libido, fatigue, and muscle loss related to menopause.
Oncology: Potential remedy for ER+ breast most cancers, as its lack of estrogenic exercise reduces the danger of stimulating most cancers cell proliferation.
Metabolic Well being: Addressing muscle losing in sufferers utilizing GLP-1 agonists (like Ozempic or Wegovy).
Males’s Well being: A possible various for males on testosterone substitute remedy (TRT) who develop gynecomastia.
Improvement Standing
As of early 2026, the U.S. Meals and Drug Administration (FDA) has offered steerage on the event pathway for AVA-291. Aviva Bio is getting ready to provoke Section I scientific trials in early 2026.
Are you curious about the scientific trial information for AVA-291 or the way it compares particularly to different non-aromatizing androgens like DHT?
That is for informational functions solely. For medical recommendation or prognosis, seek the advice of knowledgeable.
